Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by WalkOverTheStrton Aug 03, 2021 2:48pm

275 Views

Post# 33643071

This happened in PH1 (2015) so it doesn't mean the end...

 		so this happened in PH1 (2015) for those that didn't recall or know. I believe that the pause in PH1 is was due to a patient not disclosing a disease... who knows if this time it will be the case but 3 people can be narrowed in on quite well. They need to find the connection if there is one..

 		https://antibethera.com/news/antibe-therapeutics-suspends-its-phase-i-clinical-trial-due-to-safety-concerns/

 		"TORONTO, ONTARIO — (January 16, 2015) — Antibe Therapeutics Inc. (TSXV: ATE; OTCQX: ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.

 		Safety concerns centered on the finding of significant liver enzyme elevations in one subject in the highest dose cohort. Additional liver enzyme elevations were observed in other subjects in the higher dose cohorts. Antibe is concerned that, when assessed together, these liver enzyme elevations are indicative of potential hepatotoxicity.so this happened prior for those that didn't know. Believe (Jeff correct me as Im going off memory) that is was due to a patient not disclosing a disease... who knows if this time it will be the case but 3 people can be narrowed in on quite well. They need to find the connection if there is one..
 			 
 			https://antibethera.com/news/antibe-therapeutics-suspends-its-phase-i-clinical-trial-due-to-safety-concerns/
 			 
 			TORONTO, ONTARIO — (January 16, 2015) — Antibe Therapeutics Inc. (TSXV: ATE; OTCQX: ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.
 			 
 			Safety concerns centered on the finding of significant liver enzyme elevations in one subject in the highest dose cohort. Additional liver enzyme elevations were observed in other subjects in the higher dose cohorts. Antibe is concerned that, when assessed together, these liver enzyme elevations are indicative of potential hepatotoxicity.